MLFP
INSY

MPS Loria Financial Planners’s Insys Therapeutics, Inc. INSY Stock Holding History

MPS Loria Financial Planners’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,000
Closed -$9K – 380
2017
Q2 		$9K Buy
+1,000
New +$11.8K 0.01% 302

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

MPS Loria Financial Planners's INSY Position: Q3 2017 in Review

MPS Loria Financial Planners sold out of Insys Therapeutics, Inc. (INSY) in Q3 2017, closing a stake of 1,000 shares — an estimated $9K sold.

MPS Loria Financial Planners first reported a position in INSY in Q2 2017 and held it in 1 quarter. The position peaked at $9K in Q2 2017. 116 funds tracked by Wall St. Rank hold INSY as of Q3 2017.

  • MPS Loria Financial Planners reported no remaining Insys Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • MPS Loria Financial Planners sold 1,000 Insys Therapeutics, Inc. shares in Q3 2017, an estimated $9K.
  • MPS Loria Financial Planners first reported a position in Insys Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • MPS Loria Financial Planners's Insys Therapeutics, Inc. position peaked at $9K in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2017.

Based on MPS Loria Financial Planners's 13F filing for Q3 2017, filed 24 Oct 2017.